Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. More Details
Flawless balance sheet and overvalued.
Share Price & News
How has Bellerophon Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BLPH's share price has been volatile over the past 3 months.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: BLPH exceeded the US Medical Equipment industry which returned 14.8% over the past year.
Return vs Market: BLPH exceeded the US Market which returned 12.6% over the past year.
Price Volatility Vs. Market
How volatile is Bellerophon Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 year ago | Simply Wall StNeed To Know: Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) Insiders Have Been Buying Shares
1 year ago | Simply Wall StDid Changing Sentiment Drive Bellerophon Therapeutics's (NASDAQ:BLPH) Share Price Down A Painful 80%?
1 year ago | Simply Wall StA Spotlight On Bellerophon Therapeutics, Inc.'s (NASDAQ:BLPH) Fundamentals
Is Bellerophon Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate BLPH's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate BLPH's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: BLPH is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: BLPH is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BLPH's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BLPH is good value based on its PB Ratio (1.9x) compared to the US Medical Equipment industry average (4.1x).
How is Bellerophon Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BLPH is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BLPH is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BLPH is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if BLPH's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if BLPH's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BLPH's Return on Equity is forecast to be high in 3 years time
How has Bellerophon Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BLPH is currently unprofitable.
Growing Profit Margin: BLPH is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BLPH is unprofitable, but has reduced losses over the past 5 years at a rate of 29.8% per year.
Accelerating Growth: Unable to compare BLPH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BLPH is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-0.2%).
Return on Equity
High ROE: BLPH has a negative Return on Equity (-32.13%), as it is currently unprofitable.
How is Bellerophon Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: BLPH's short term assets ($60.3M) exceed its short term liabilities ($6.6M).
Long Term Liabilities: BLPH's short term assets ($60.3M) exceed its long term liabilities ($2.7M).
Debt to Equity History and Analysis
Debt Level: BLPH is debt free.
Reducing Debt: BLPH has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BLPH has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: BLPH has sufficient cash runway for 2.8 years if free cash flow continues to grow at historical rates of 32.1% each year.
What is Bellerophon Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BLPH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BLPH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BLPH's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BLPH's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BLPH's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Fabian Tenenbaum (46 yo)
Mr. Fabian Tenenbaum, M.B.A, has been the Chief Executive Officer of Bellerophon Therapeutics, Inc. since November 2016. Mr. Tenenbaum served as Chief Financial Officer and Chief Business Officer of Beller ...
CEO Compensation Analysis
Compensation vs Market: Fabian's total compensation ($USD1.40M) is above average for companies of similar size in the US market ($USD589.17K).
Compensation vs Earnings: Fabian's compensation has been consistent with company performance over the past year.
|CEO & Director||3.83yrs||US$1.40m||0.29% |
|CFO & Secretary||2.67yrs||US$488.41k||0.046% |
|Chief Regulatory & Safety Officer||5.33yrs||US$533.98k||0.13% |
|Vice President of Business Operations||no data||no data||0.074% |
|Vice President of Clinical Operations & Administration||5yrs||no data||0.098% |
|Chief Medical Officer||0.083yr||no data||0.042% |
Experienced Management: BLPH's management team is considered experienced (3.8 years average tenure).
|CEO & Director||3.83yrs||US$1.40m||0.29% |
|Independent Director||5.25yrs||US$66.32k||1.28% |
|Independent Director||2.5yrs||US$56.32k||0.021% |
|Independent Director||4.58yrs||US$71.32k||0.015% |
|Independent Director||5.33yrs||US$56.32k||0.013% |
|Chairman of the Board||6.25yrs||US$200.00k||1.39% |
|Independent Director||6.58yrs||US$61.32k||0.062% |
|Independent Director||2.83yrs||US$56.32k||0.64% |
|Independent Director||1.5yrs||US$74.45k||0% |
Experienced Board: BLPH's board of directors are considered experienced (4.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: BLPH insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 106.8%.
Bellerophon Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Bellerophon Therapeutics, Inc.
- Ticker: BLPH
- Exchange: NasdaqCM
- Founded: 2009
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$100.392m
- Shares outstanding: 9.50m
- Website: https://www.bellerophon.com
Number of Employees
- Bellerophon Therapeutics, Inc.
- 184 Liberty Corner Road
- Suite 302
- New Jersey
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|BLPH||NasdaqCM (Nasdaq Capital Market)||Yes||Common Stock||US||USD||Feb 2015|
|6L7A||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Feb 2015|
|0HMP||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Feb 2015|
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its products include INOpul ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/09/20 06:07|
|End of Day Share Price||2020/09/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.